Want to see KPTI full AI Analyst Report?
KPTI Stock Chart & Stats
$8.61
-$0.04(-5.28%)
At close: 4:00 PM EST
$8.61
-$0.04(-5.28%)
Day’s Range― - ―
52-Week Range$3.65 - $10.99
Previous CloseN/A
Volume220.82K
Average Volume (3M)228.24K
Market Cap
$231.16M
Enterprise Value$353.06M
Total Cash (Recent Filing)$90.85M
Total Debt (Recent Filing)$230.87M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Jul 30, 2026EPS Estimate
-1.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.84
Shares Outstanding22,662,943
10 Day Avg. Volume494,784
30 Day Avg. Volume228,238
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.27
Price to Sales (P/S)0.55
P/FCF Ratio-1.07
Enterprise Value/Market Cap1.53
Enterprise Value/Revenue2.34
Enterprise Value/Gross Profit2.43
Enterprise Value/Ebitda-2.39
Forecast
1Y Price Target
$13.00Price Target Upside50.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-4.08
Revenue Forecast (FY)$137.21M
Bulls Say, Bears Say
Bulls Say
High Product Gross MarginsExceptional gross margins (~96%) mean most incremental selinexor revenue converts to gross profit, creating strong product-level economics. Over a 2–6 month horizon this underpins the unit economics for scaling sales and can fund incremental R&D or commercialization if revenue expands.
Robust Phase III SENTRY EfficacySENTRY's strong spleen responses and an overall survival signal support a disease‑modifying profile versus JAK inhibitor alone. Durable Phase III efficacy materially strengthens regulatory and payer arguments, improves launch potential in myelofibrosis and can sustain long-term market share if confirmed.
Commercial Infrastructure & Revenue TractionQuarterly revenue improvement and an established commercial organization reduce execution risk for label expansion and launches. Combined with a cash buffer, this infrastructure supports market access, physician uptake and scaled commercialization if upcoming readouts convert into approvals and demand.
Bears Say
Short Cash RunwayA runway only into late Q3 2026 is a persistent liquidity constraint: without significant revenue acceleration or milestone receipts, the company will likely need capital within months. That compresses strategic optionality, increases financing/dilution pressure and elevates execution risk.
Deeply Negative EquitySubstantially negative shareholders' equity (~-$266M TTM) materially weakens financial flexibility and heightens refinancing and going‑concern sensitivity. Over the medium term this limits non-dilutive funding options, raises cost of capital and constrains balance-sheet support for growth.
Persistent Net Losses And High Operating BurnOngoing structural losses and large R&D+SG&A guidance mean high cash burn that will continue absent material commercial scale or milestone income. This makes the business highly execution‑dependent; failed or delayed readouts would prolong funding needs and increase dilution risk.
Karyopharm Therapeutics News
KPTI FAQ
What was Karyopharm Therapeutics’s price range in the past 12 months?
Karyopharm Therapeutics lowest stock price was $3.65 and its highest was $10.99 in the past 12 months.
What is Karyopharm Therapeutics’s market cap?
Karyopharm Therapeutics’s market cap is $231.16M.
When is Karyopharm Therapeutics’s upcoming earnings report date?
Karyopharm Therapeutics’s upcoming earnings report date is Jul 30, 2026 which is in 19 days.
How were Karyopharm Therapeutics’s earnings last quarter?
Karyopharm Therapeutics released its earnings results on May 14, 2026. The company reported -$1.24 earnings per share for the quarter, beating the consensus estimate of -$1.417 by $0.177.
Is Karyopharm Therapeutics overvalued?
According to Wall Street analysts Karyopharm Therapeutics’s price is currently Undervalued.
Does Karyopharm Therapeutics pay dividends?
Karyopharm Therapeutics does not currently pay dividends.
What is Karyopharm Therapeutics’s EPS estimate?
Karyopharm Therapeutics’s EPS estimate is -1.31.
How many shares outstanding does Karyopharm Therapeutics have?
Karyopharm Therapeutics has 22,662,943 shares outstanding.
What happened to Karyopharm Therapeutics’s price movement after its last earnings report?
Karyopharm Therapeutics reported an EPS of -$1.24 in its last earnings report, beating expectations of -$1.417. Following the earnings report the stock price went up 0.565%.
Which hedge fund is a major shareholder of Karyopharm Therapeutics?
Currently, no hedge funds are holding shares in KPTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Karyopharm Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.00 (50.99% Upside)
$13.00 (50.99% Upside)
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.3%
Last 30 Days ▼ 6.2%
Last 30 Days ▼ 6.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-53.70%
12-Months-Change
Fundamentals
Return on Equity
73.11%
Trailing 12-Months
Asset Growth
2.90%
Trailing 12-Months
Company Description
Karyopharm Therapeutics
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
KPTI Company Deck
KPTI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys strong clinical momentum and significant near-term catalysts: compelling Phase III SENTRY results with a statistically robust spleen response and an intriguing overall survival signal, completed enrollment in EC042 with prior SIENDO data showing deep and durable PFS benefit, ASCO presentation and planned mid-2026 manuscript, and quarter-over-quarter revenue improvement driven by gross-to-net gains. These positives are tempered by competitive pressure that reduced underlying demand for XPOVIO, gross-to-net volatility, continued net losses and high operating spend, and a limited cash runway into late Q3 2026 that may necessitate additional financing or milestone events. Regulatory timing and the need for further data granularity (e.g., deaths attribution) add some near-term uncertainty. On balance, the clinical and strategic highlights are material and potentially value-creating, though execution and financing risks remain.View all KPTI earnings summariesKPTI Stock 12 Month Forecast
Average Price Target
$13.00
▲(50.99% Upside)
Technical Analysis
Actinium Pharmaceuticals
―
Bioxcel Therapeutics
―
Lantern Pharma
―
Century Therapeutics
―
Medicus Pharma Ltd
―
Ownership Overview
3.66% Insiders
18.52% Mutual Funds
<0.01% Other Institutional Investors
70.45% Public Companies and
Individual Investors